MSD Secures Approval for Subcutaneous Formulation of Keytruda in Japan

Same Cancer Indications as Existing IV Injection

Following the US, Europe, and Canada, Japan Approves ALT-B4-Based Product, Expanding Commercialization

Alteogen announced on September 18 that MSD's Keytruda SC (marketed as Keyject in Japan), a subcutaneous injection (SC) formulation that uses Alteogen's proprietary formulation change platform Hybrozyme and its core ingredient ALT-B4 (ingredient name: berahyaluronidase alpha), has received manufacturing and sales approval in Japan.


Keytruda SC is a combination product that applies Alteogen's berahyaluronidase alpha to MSD's immunotherapy Keytruda (ingredient name: pembrolizumab), enabling the existing intravenous (IV) formulation of Keytruda to be administered subcutaneously.


Aerial view of Alteogen headquarters and research center. Alteogen

Aerial view of Alteogen headquarters and research center. Alteogen

View original image

With this approval, Keytruda SC can now also be used in Japan. While the conventional IV formulation is administered intravenously over approximately 30 minutes, the SC formulation can be administered in just one to two minutes.


After securing approvals in the United States, Europe, and Canada, Keytruda SC has now received authorization in Japan as well, thereby expanding its commercial reach in major markets. Alteogen explained that ALT-B4 is a recombinant human hyaluronidase that temporarily degrades hyaluronic acid under the skin, facilitating the spread and absorption of the drug in subcutaneous tissue.


In August, Alteogen disclosed that it would receive a first sales milestone payment of USD 25 million (approximately KRW 34.5 billion) from MSD following the launch of Keytruda SC. This is the first of Keytruda SC's sales milestones covered under the licensing agreement between the two companies, which could total up to USD 1 billion (approximately KRW 1.38 trillion).



This approval in Japan is based on phase 3 clinical trial MK-3475A-D77, conducted in patients with advanced or recurrent non-small cell lung cancer. In this trial, the SC formulation of Keytruda combination therapy was compared to the IV formulation, and non-inferiority of the SC formulation was confirmed. No new safety concerns were identified compared to the existing IV formulation, and MSD stated that the safety profile of the SC formulation was consistent with previous treatments.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing